Every Form 4 that Monogram Technologies Inc. (MGRM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MGRM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MGRM filings page.
Monogram Technologies Inc. (MGRM) reported on Form 4 that a director disposed of 8,000 stock options on 10/07/2025, leaving 0 derivative securities beneficially owned (direct ownership). This followed the merger in which the company became a wholly owned subsidiary of Zimmer Biomet Holdings, Inc.
At the merger’s Effective Time, each outstanding option was canceled and converted into the right to receive a cash payment equal to $4.04 per share minus the exercise price and one contractual CVR, subject to terms. Options with a per‑share exercise price greater than $16.41 were canceled for no consideration, per the disclosed mechanics.
Monogram Technologies (MGRM) reported an insider equity award. A director filed a Form 4 for a grant (Code A) of stock options on 01/08/2025 covering 5,000 underlying shares at an exercise price of $2.50 per share. The options are listed as exercisable on 01/08/2032 and expiring on 01/08/2035. Following the reported transaction, the filer shows 8,000 derivative securities beneficially owned, held directly. The company notes it uses the Black‑Scholes‑Merton model to determine the fair value of stock awards.
Monogram Technologies insider Richard Van Kirk filed a Form 4 showing that 7,000 stock options were cancelled on 10/07/2025 as part of the company’s merger with Zimmer Biomet. Under the merger terms, each outstanding option converted into a cash payment equal to the excess of $4.04 per share over the option’s exercise price plus a contractual contingent value right (CVR) where applicable, or into a CVR alone for options with higher exercise prices; options with exercise prices above $16.41 were cancelled without consideration. The filing is signed by an attorney-in-fact for Mr. Van Kirk and reflects the post-closing treatment of equity awards when the issuer became a wholly owned subsidiary of Zimmer Biomet.
Monogram Technologies (MGRM) insider reporting of merger-related cancellations. The filing shows that on 10/07/2025 a reporting person identified as a company director had 3,532,622 shares of common stock disposed of and now reports 0 shares beneficially owned. Those shares were converted at the merger effective time into a cash payment of $4.04 per share plus one contractual contingent value right (CVR) per share that can pay up to additional amounts tied to five milestones (examples include $1.04, $1.08 and up to $3.43 depending on milestone achievement).
The filing also reports cancellation of 1,475,000 stock options, which were converted into cash equal to the excess of the $4.04 cash amount over the option exercise price and one CVR per option share; options with exercise prices above certain thresholds were cancelled for no consideration. The form is a Section 16 Form 4 reporting the post-closing ownership and the merger consideration structure.
Monogram Technologies insider sale and option cancellations tied to merger with Zimmer Biomet. The report shows Kamran Shamaei, Chief Technology Officer, disposed of 2,926 shares on 10/07/2025 and had 1,310,000 stock options cancelled the same day as part of the merger's terms. At the effective time each outstanding share was converted into $4.04 cash plus one contractual contingent value right (CVR) that may pay up to additional amounts across five milestones (for example, $1.04 for the First Milestone and up to $3.43 for later milestones). Cancelled options converted into a cash payment equal to the excess of the cash consideration over the option exercise price plus one CVR, except certain high‑strike options were cancelled for no consideration. The filing is an update reflecting the merger consideration and resulting insider holdings.
Monogram Technologies (MGRM) insider Benjamin Sexson, the company's Chief Executive Officer and a director, reported on 10/07/2025 the disposition of his entire beneficial holdings following a merger. At the merger Effective Time, each outstanding common share was converted into $4.04 in cash plus one contingent value right (CVR) per share. Mr. Sexson reported disposition of 4,006,330 shares and cancellation/conversion of 1,560,000 stock options for cash and CVRs, leaving him with 0 shares and 0 options reported post-transaction. The CVRs carry potential contingent payments including $1.04, $1.08, and up to $3.43 per CVR for specified milestones.
Monogram Technologies Inc. became a wholly owned subsidiary of Zimmer Biomet through a merger effective 10/07/2025. At the effective time, all outstanding options were cancelled and converted according to the merger terms: optionholders received a cash payment equal to the excess of $4.04 over each option's exercise price plus one contractual contingent value right (CVR), except where an option's exercise price produced different treatment under the CVR formula. The filing shows a reported derivative disposition of 40,000 stock options by a reporting director, recorded as cancelled and converted into the merger consideration. Some options with exercise prices above $16.41 were cancelled for no consideration under the merger terms.
Noel Knape, Chief Financial Officer, reported a Form 4 disclosing changes in ownership tied to a merger with Zimmer Biomet. At the merger each outstanding share converted into $4.04 in cash plus one contractual contingent value right (CVR) that can pay up to specified milestone amounts (including $1.04, $1.08 and up to $3.43 for later milestones). The filing shows 296,385 shares of common stock were disposed and 115,000 stock options were cancelled and converted per the merger terms, leaving 0 shares and 0 options beneficially owned following the transactions.
Monogram Technologies Inc. (MGRM) director Paul Riss reported a grant of 10,000 stock options on 01/08/2025. The options have an exercise price of $2.50 and are shown with an exercisable date of 01/08/2032 and an expiration date of 01/08/2035, covering 10,000 underlying shares. After the reported transaction the filing shows 40,000 shares beneficially owned by the reporting person in a direct form. The form notes the company uses the Black-Scholes-Merton model to value awards and includes the reporting person signature dated 09/30/2025.
Douglas Unis, a director of Monogram Technologies Inc. (MGRM), received a stock option award and reports his beneficial ownership. The Form 4 discloses a grant of a stock option on 01/08/2025 to purchase 35,000 shares of common stock with an exercise price of $2.50. The option becomes exercisable on 01/08/2032 and expires on 01/08/2035. After this transaction, the filing reports 1,475,000 shares beneficially owned by Mr. Unis held directly. The form includes a note that the company uses the Black-Scholes model to value stock awards.
Monogram Technologies insider option grant to CTO reported. The filing shows Kamran Shamaei, identified as Chief Technology Officer and a director/officer, was granted a stock option on 01/08/2025 to acquire 250,000 shares of common stock at an exercise price of $2.50 per share. The option becomes exercisable on 01/08/2032 and expires on 01/08/2035. The reported transaction increases direct beneficial ownership by 250,000 shares. The explanation notes the company uses the Black-Scholes model to value stock awards.
Noel Knape, Chief Financial Officer and Director of Monogram Technologies Inc. (MGRM), reported a transaction on Form 4 showing an award of derivative securities. The filing reports that on 01/08/2025 Mr. Knape was granted 40,000 stock options with an exercise price of $2.50. The options have a date exercisable of 01/08/2032 and an expiration date of 01/08/2035, and the underlying security is common stock. The Form identifies Mr. Knape’s address in Austin, TX and is signed by him on 09/30/2025. The filing includes an explanatory note that the company uses the Black-Scholes-Merton model to determine fair value of stock awards.